IL-33 Agonist and Antagonist Modulation for Immune Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need to effectively treat inflammatory and immune disorders, particularly those involving the IL-1 family of cytokines, which contribute to conditions like rheumatoid arthritis and cancer, as current treatments are inadequate in modulating immune responses and managing pathological consequences.
Innovation Solution
The use of agonists and antagonists of IL-33 or its receptor to modulate immune and inflammatory conditions, including asthma, allergies, arthritis, and responses to intracellular pathogens, through administration of IL-33 or its nucleic acid, or antibodies that specifically bind to the IL-33 receptor complex, thereby influencing immune cell counts and cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory and immune disorders are used, then existing therapeutic options are available, but they are inadequate in modulating immune responses and managing pathological consequences
Solution Approach 1:
The patent uses IL-33 and its receptor as intermediary molecules to mediate immune responses. IL-33 acts as a cytokine that binds to its receptor complex (IL-33R) to modulate immune cell activity, providing a targeted mechanism to control inflammatory and immune disorders that existing treatments cannot adequately address.
Solution Approach 2:
The patent employs agonists and antagonists of IL-33 to change the biological activity parameters of the IL-33 signaling pathway. By administering agents that either activate (agonists) or block (antagonists) the IL-33 receptor, the patent can precisely modulate immune responses to treat various inflammatory and immune-related conditions.
2Adaptability or versatility
If IL-33 or its receptor is targeted to modulate immune responses, then immune disorders can be treated, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent extracts and isolates specific components of the IL-33 signaling pathway (IL-33 cytokine, IL-33 receptor complex, agonists, and antagonists) as discrete therapeutic agents. This extraction allows for targeted administration of specific molecules that can modulate immune responses without requiring complex multi-component systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the modulation of immune disorders by regulating immune responses, reducing inflammation, and potentially treating conditions such as asthma, arthritis, and cancer by targeting IL-33 or its receptor, thereby providing a therapeutic option for managing inflammatory and immune-related diseases.
Implementation Method 1
IL-33, and a receptor for IL-33... IL-33 or its receptor, thereby providing a therapeutic option for managing inflammatory and immune-related diseases
Data Source
AI summary
Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.